



Kimberley S.M. Benschop,* Janke Schinkel,*
Manon E. Luken,† Peter J.M. van den Broek,†
Matthias F.C. Beersma,‡ Negassi Menelik,§ 
Hetty W.M. van Eijk,* Hans L. Zaaijer,* 
Christina M.J.E. VandenBroucke-Grauls,* 
Marcel G.H.M. Beld,* and Katja C. Wolthers*
We identified a novel human parechovirus (HPeV) type
(K251176-02) from a neonate with fever. Analysis of the
complete genome showed K251176-02 to be a new HPeV
genotype. Since K251176-02 could not be neutralized with
antibodies against known HPeV serotypes 1–3, it should be
classified as a fourth HPeV serotype.
I
nfections with human parechoviruses (HPeVs) are com-
monly associated with mild gastrointestinal and respira-
tory symptoms in young children (1–3), but more severe
conditions, such as flaccid paralysis (4) and encephalitis
(5), have also been described. Recently, a new serotype
(HPeV3) has been isolated, which has been associated
with transient paralysis (6) and neonatal sepsis (7).
HPeV1 and HPeV2 were previously known as the
enteroviruses echovirus 22 and 23 but were reclassified
into a new genus within the family Picornaviridae after
phylogenetic analysis showed that parechoviruses were
distinct from other picornaviruses (1–3,8–11). HPeVs have
predominantly been isolated from young children, and
increasing evidence shows that HPeVcan cause serious ill-
ness in these patients.
We recently showed that infection with HPeV3 is asso-
ciated with younger age and more severe disease than is
infection with HPeV1 (12). During the screening of patient
samples, we identified 1 aberrant HPeV type. Phylogenetic
analysis of the full-length sequence and viral neutraliza-
tion assays showed that the isolate designated K251176-02
is a new HPeV genotype and serotype.
The Study
Viral culture of the stool of a 6-day-old patient with a
2-day history of high fever and poor feeding and no histo-
ry of gastrointestinal or respiratory symptoms showed
enterovirus cytopathic effects. However, PCR targeted at
the 5′ untranslated region (UTR) of enterovirus (13) was
negative, whereas a 5′ UTR PCR specific for HPeV (12)
was positive.
Results of sequencing the VP1 region (12) suggested
that K251176-02 was a novel HPeV genotype. Therefore,
the full-length sequence was determined. Combinations of
consensus primers were used to generate partially overlap-
ping amplicons that covered the complete genome.
Amplicons were sequenced according to a primer walking
strategy. The 5′ UTR was amplified by using the 5′ RACE
System (Invitrogen, Carlsbad, CA, USA). Because a
primer composed of the first 22 nucleotides (nt) of pub-
lished consensus parechovirus sequences was used to
amplify the 5′ UTR proximal end, these 22 nt could not be
determined with absolute certainty (8). The 3′ UTR end
was amplified with a tagged oligo-dT primer.
The complete genome of K251176-02 was 7,348 nt
long, containing a 5′ UTR of 708 nt, a large single open
reading frame (ORF) of 6,549 nt, and a 3′ UTR of 91 nt
followed by a poly(A) tract. The full-length sequence of
K251176-02 has been deposited in GenBank under acces-
sion no. DQ315670.
We found a best-match nucleotide identity (14) of
72.2% in the VP1 gene with HPeV2 CT86-6760, which
suggests that K251176-02 is most closely related to
HPeV2 CT86-6760. Indeed, phylogenetic analysis of the
capsid nucleotide sequence based on Jukes and Cantor dis-
tances showed K251176-02 to cluster with HPeV2 CT86-
6760 (Figure 1A). However, the genetic distance was
considerable (0.327) and comparable to the genetic dis-
tance between HPeV1 Harris and HPeV2 Williamson
(0.332). Phylogenetic analysis of the nonstructural region
showed that K251176-02 clustered with the HPeV3 proto-
types A308-99 and Can82853-01 (Figure 1B).
To identify recombination events between the different
HPeV prototypes, a SimPlot analysis was performed on
the known full-length nucleotide HPeV genomes against
K251176-02. The SimPlot analysis (Figure 2) showed the
differential similarity of K251176-02 with HPeV2 CT86-
6760 in the highly variable P1 region and with HPeV3 in
the more conserved P2–P3 region. This finding may be the
result of a recombination event.
The secondary structure of the 5′ UTR of K251176-02,
determined by the Mfold program of Zuker and Turner
(http://mfold2.wustl.edu), was predicted to be highly struc-
tured and was characterized by a stable hairpin at the prox-
imal end that was also found in known HPeV prototypes
(8,11, data not shown). The predicted secondary structure
of the 3′ UTR of K251176-02 contained the same 1-stem
loop organization as the HPeV prototypes and was similar
to the secondary structure of HPeV1 Harris and HPeV2
Williamson and CT86-6760 (15).
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with the HPeV prototypes showed an amino acid identity
of 86.9% to 90.1% (Table 1). This amount is in the same
range of amino acid identity as observed between known
HPeV protoypes. For the VP1 gene, the greatest amino
acid identity was observed with HPeV2 CT86-6760
(80.4%). In the nonstructural region, identity was greater
to HPeV3, with 98.1% identity in the polymerase gene
(3Dpol).
Comparison of the deduced amino acid sequence in the
capsid region of K251176-02 with the HPeV prototypes
showed that the sequences that are predicted to be part of
the  β-barrel structure (6,10,11) are well conserved in
K251176-02. Like HPeV1 and HPeV2, K251176-02 also
contained an RGD motif at the C-terminal end of the VP1
gene, which was absent in HPeV3 (6,7,15). K251176-02
also contained the common motifs X2GXGK(S/T) and
DDLXQ (2C gene), which are predicted to have a helicase
function. The active-site cysteine of the protease 3C is in
the context of GXCG, and the active site of polymerase
3Dpol contains the conserved sequence YGDD. The well-
conserved motifs within the 3Dpol gene (KDELR, PSG, and
FLKR) were also found in K251176-02 (6,9,11).
In summary, K251176-02 represents a new genotype in
the genus Parechovirus. To confirm that K251176-02 is
also a new serotype, a neutralization assay was performed.
Table 2 shows that K251176-02 could not be neutralized
by antisera directed against HPeV1 Harris, HPeV2
Williamson, and HPeV3 A308-99, which confirms that
K251176-02 is a new genotype that can be classified as a
fourth HPeV serotype.
Conclusions
HPeVs are classified in the genus Parechovirus in the
family  Picornaviridae. The recently identified HPeV3
has been associated with severe illness in young children
in several studies (6,7,12). This association has increased
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Figure 1. Unrooted phylogenetic trees showing the relationship
between K251176-02 (DQ315670) and the prototype strains
human parechovirus serotype 1 (HPeV1) Harris (S45208), HPeV2
Williamson (AJ005695), HPeV2 CT86-6760 (AF055846), HPeV3
A308-99 (AB084913), and Can82853-01 (AJ889918) based on
nucleotide Jukes and Cantor substitution model for the capsid
region (A) and the nonstructural region (B). The tree was con-
structed by the neighbor-joining method as implemented in MEGA
version 3.1. Gaps introduced for optimal alignment were not con-
sidered informative and were excluded from the analyses by com-
plete deletion. Numbers represent the frequency of occurrence of
nodes in 1,000 bootstrap replicas. The use of other evolution mod-
els did not influence the tree topology.
Figure 2. Similarity plot of human parechovirus serotype 1
(HPeV1) Harris (S45208), HPeV2 Williamson (AJ005695), HPeV2
CT86-6760 (AF055846), HPeV3 A308-99 (AB084913), and
Can82853-01 (AJ889918) against K251176-02. Each curve is a
comparison between the K251176-02 genome and an HPeV pro-
totype. Each point represents the percentage identity within a slid-
ing window 600 bp wide, centered on the position plotted, with a
step size of 20 bp. Positions containing gaps were excluded from
the comparison by gap stripping, and Jukes and Cantor correction
was applied. Similarity plots of the full-length sequences of the
HPeV prototypes were generated by using SimPlot version 2.5.the awareness of HPeVs as relevant pathogens in young
children.
We identified a new HPeV genotype in a stool speci-
men from a neonate with high fever. Since classification
criteria based on genotyping have not been defined for
HPeVs, we used the criteria proposed by Oberste et al. (14)
for the classification of new enteroviral genotypes.
According to these criteria, a new genotype is defined
when a best-match nucleotide identity of <70% is found in
the VP1 gene. A 70%–75% best-match nucleotide identity
indicates further characterization is needed. Therefore,
neutralization assays were conducted; these assays showed
that K251176-02 did not neutralize with antisera directed
against the 3 known HPeV serotypes. This finding indi-
cates that K251176-02 is a new genotype that can be clas-
sified as a fourth HPeV serotype.
The patient from whom K251176-02 was isolated had
high fever but no signs of neonatal sepsis, as has been
found in infections with HPeV3 (6,7,12). Previous data
suggest differences in severity of disease between the dif-
ferent HPeV serotypes (12); however, more data are need-
ed to elucidate epidemiologic and pathogenic features of
the different HPeV serotypes, including K251176-02.
HPeV2 CT86–6760 was genotypically as distinct from
HPeV2 Williamson as from other HPeV types (Table 1).
The existence of 2 genotypically divergent HPeV
serotypes 2 is surprising and needs to be elucidated further.
This finding, however, argues in favor of a universal typ-
ing method that is based on molecular characteristics
(genotyping) instead of serotyping, provided classification
criteria are well defined.
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